NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and G…
Medical - Instruments & Supplies
JE, Saint Helier [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about NovoCure Limited's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | -1.113 | - | 61 | - | -118 | - | -6 | - | -7 | - | 34 |
| 2016 | -3.6700 | -0.917 | 33 | 79 | -111 | -120 | -103 | -105 | -103 | -104 | 72 | 44 |
| 2017 | -1.5400 | -0.650 | 82 | 177 | -131 | -63 | -115 | -42 | -115 | -40 | 110 | 127 |
| 2018 | -0.7000 | -0.652 | 177 | 247 | -61 | -55 | -39 | -31 | -39 | -29 | 122 | 135 |
| 2019 | -0.6900 | -0.113 | 248 | 351 | -63 | -6 | -33 | 4 | -33 | 3 | 151 | 276 |
| 2020 | -0.0744 | 0.262 | 351 | 494 | -7 | 27 | 0.91 | -53 | 0.91 | -63 | 184 | 277 |
| 2021 | 0.2000 | -0.416 | 494 | 535 | 19 | -157 | 30 | -106 | 30 | -119 | 225 | 300 |
| 2022 | -0.5600 | -0.824 | 535 | 537 | -58 | -55 | -44 | -42 | -44 | -40 | 263 | 270 |
| 2023 | -0.8800 | -2.024 | 537 | 509 | -92 | -207 | -89 | -50 | -89 | -48 | 306 | 298 |
| 2024 | -1.9500 | -1.307 | 509 | 597 | -207 | -139 | -176 | -64 | -232 | -76 | 390 | 335 |
| 2025 | - | -1.583 | - | 624 | - | -165 | - | -67 | - | -80 | - | 351 |
| 2026 | - | -1.471 | - | 691 | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | -1.180 | - | 785 | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | -0.825 | - | 899 | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
Equal-Weight
Prev. Grade
Equal-Weight
Dec. 11, 2024
Equal-Weight
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
+13.28% + $4.09 · MISS
Nov. 6, 2024Price Then
$16.62
Price Target
$26.71
Price Now
$30.80